.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,316,443

« Back to Dashboard

Claims for Patent: 6,316,443

Title: Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a .beta.-adrenergic antagonist
Abstract:Combinations of a .beta.-adrenergic antagonist and a topical carbonic anhydrase inhibitor are particularly useful in the treatment of ocular hypertension, especially in patients insufficiently responsive to treatment with .beta.-adrenergic antagonists.
Inventor(s): Baldwin; John J. (Gwynedd Valley, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/532,704
Patent Claims: 1. An ophthalmic formulation for treatment of ocular hypertension in a subject whose intraocular pressure is inadequately controlled by .beta.-adrenergic antagonists comprising an ophthalmologically acceptable carrier, 0.5 to 5% (w/w) of a carbonic anhydrase inhibitor of the structure: ##STR3##

the individual diastereomers, the individual enantiomers or mixtures thereof, or an ophthalmologically acceptable salt thereof, wherein:

A is carbon or nitrogen;

Z is NHR or --OR;

R is C.sub.1-6 alkyl, either straight or branched chain;

R.sup.1 is

(a) hydrogen

(b) C.sub.1-3 alkyl, or

(c) C.sub.1-4 alkoxy-C.sub.1-4 alkyl; and

X is --SO.sub.2 -- or --C(O)--;

and 0.01 to 1.0% of a .beta.-adrenergic antagonist selected from betaxolol, bufenolol, carteolol, levobunolol, metipranolol, and timolol, or an ophthalmologically acceptable salt thereof.

2. The formulation of claim 1 wherein A is carbon, Z is --NHR, and X is --SO.sub.2 --.

3. The formulation of claim 2 wherein:

R is

a) --CH.sub.2 CH.sub.3 ;

b) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

c) --CH.sub.2 CH(CH.sub.3).sub.2,

R.sup.1 is

a) hydrogen;

b) --CH.sub.3 ;

c) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

d) --CH.sub.2 CH.sub.2 CH.sub.2 OCH.sub.3.

4. The formulation of claim 3 wherein b-adrenergic antagonist is timolol or an ophthalmologically acceptable salt thereof.

5. The formulation of claim 1 wherein b-adrenergic antagonist is betaxolol or an ophthalmologically acceptable salt thereof.

6. The formulation of claim 3 wherein R is --CH.sub.2 CH.sub.3 ; and R.sup.1 is --CH.sub.3 ; or R is --CH.sub.2 CH.sub.2 CH.sub.3 ; and R.sup.1 is --CH.sub.2 CH.sub.2 CH.sub.2 OCH.sub.3 ; or R is --CH.sub.2 CH.sub.3 ; and R.sup.1 is --CH.sub.2 CH.sub.2 CH.sub.3 ; or R is --CH.sub.2 CH(CH.sub.3).sub.2, and R.sup.1 is hydrogen.

7. The formulation of claim 1 wherein the concentration of carbonic anhydrase inhibitor is 0.7 to 2.0%.

8. The formulation of claim 1 further comprising 0.1% to 2% of a gum.

9. The formulation of claim 8 wherein the gum is gellan gum.

10. A method of treating ocular hypertension which comprises the topical ocular administration, to a patient in need thereof an effective amount of an ophthalmic formulation comprising an ophthalmologically acceptable carrier, 0.5 to 5% (w/w) of a carbonic anhydrase inhibitor of the structure: ##STR4##

the individual diastereomers, the individual enantiomers or mixtures thereof, or an ophthalmologically acceptable salt thereof, wherein:

A is carbon or nitrogen;

Z is NHR or --OR;

R is C.sub.1-6 alkyl, either straight or branched chain;

R.sup.1 is

(a) hydrogen

(b) C.sub.1-3 alkyl, or

(c) C.sub.1-4 alkoxy-C.sub.1-4 alkyl; and

X is --SO.sub.2 -- or --C(O)--;

and 0.01 to 1.0% of a .beta.-adrenergic antagonist selected from betaxolol, bufenolol, carteolol, levobunolol, metipranolol, and timolol, or an ophthalmologically acceptable salt thereof.

11. The method according to claim 10 which comprises the topical ocular administration of an effective amount of an ophthalmic formulation to a patient in need thereof wherein: the .beta.-adrenergic antagonist is timolol, betaxolol or an ophthalmologically acceptable salt thereof and

R is

a) --CH.sub.2 CH.sub.3 ;

b) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

c) --CH.sub.2 CH(CH.sub.3).sub.2 ; and

R.sup.1 is

a) hydrogen;

b) --CH.sub.3 ;

c) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

d) --CH.sub.2 CH.sub.2 OCH.sub.3.

12. The method according to claim 10 wherein:

A is carbon;

Z is NHR;

X is --SO.sub.2 --;

R is

a) --CH.sub.2 CH.sub.3 ;

b) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

c) --CH.sub.2 CH(CH.sub.3).sub.2 ; and

R.sup.1 is

a) hydrogen;

b) --CH.sub.3 ;

c) --CH.sub.2 CH.sub.2 CH.sub.3 ; or

d) --CH.sub.2 CH.sub.2 OCH.sub.3.

13. The method according to claim 11 wherein the .beta.-adrenergic antagonist is timolol or an ophthalmologically acceptable salt thereof.

14. The method according to claim 12 wherein R is --CH.sub.2 CH.sub.3 and R.sup.1 is --CH.sub.3 ; or R is --CH.sub.2 CH.sub.2 CH.sub.3 and R.sup.1 is --CH.sub.2 CH.sub.2 CH.sub.2 OCH.sub.3.

15. A topical ophthalmic formulation for treatment of ocular hypertension in a patient in need thereof comprising an ophthalmologically acceptable carrier, 0.5 to 5% (w/w) of a carbonic anhydrase inhibitor of the structure: ##STR5##

the individual diastereomers, the individual enantiomers or mixtures thereof, or an ophthalmologically acceptable salt thereof, wherein:

A is carbon;

Z is NHR;

R is C.sub.1-6 alkyl, either straight or branched chain;

R.sup.1 is C.sub.1-3 alkyl, and

X is --SO.sub.2 --;

and 0.01 to 1.0% of timolol, betaxolol or an ophthalmologically acceptable salt thereof, wherein the ratio of carbonic anhydrase inhibitor to .beta.-adrenergic antagonists is greater than one.

16. The formulation of claim 15 wherein R is --CH.sub.2 CH.sub.3 and R.sup.1 is --CH.sub.3.

17. The formulation of claim 15 further comprising from about 0.1 to about 2% gellan gum.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc